UPMED

UPMED : Understanding how healthcare Professionals Make and Experience their Decisions in HIV cure/remission clinical trials

Funder: « HIV Cure 2024 » of Sidaction and AIDS Fonds
Principal Investigators: Christel PROTIERE
Collaborators: TRT-5 CHV
Project Start Date: March 2026

Contact : Christel PROTIERE christel.protiere@inserm.fr and Sarah LEFEBVRE sarah.lefebvre@inserm.fr

As part of a broader research project on the representations and experiences of all stakeholders involved in HIV cure and remission research1-7, the UPMED study aims to document the experiences of physicians and to identify the main factors influencing their decisions in the context of HIV cure/remission clinical trials in France.

This study focuses on two key decisions in the course of these trials: the selection of people living with HIV who are offered participation, and the decision to restart antiretroviral treatment in the context of an analytical treatment interruption.

Bringing together research teams in the social sciences, clinical teams, and a community-based organization, the study includes a qualitative component (individual interviews and observations of medical consultations), a quantitative component (self-administered questionnaires and clinical vignettes), and a workshop.

Mots clés : Clinical trials, HIV Cure, Physicians, Representations, Experiences, Interactions

Publications :

  1. Protière C, Spire B, Mora M, et al. Patterns of patient and healthcare provider viewpoints regarding participation in HIV cure-related clinical trials. Findings from a multicentre French survey using Q methodology (ANRS-APSEC). PLOS ONE 2017;12(11):e0187489; doi: 10.1371/journal.pone.0187489.
  2. Préau M, Doumergue M, Protiere C, et al. Acceptability of HIV cure-related trials: the challenges for physicians and people living with HIV (ANRS-APSEC). AIDS Care 2018;30(7):914–920; doi: 10.1080/09540121.2018.1426825.
  3. Fiorentino M, Protière C, Sagaon-Teyssier L, et al. What is the effect of self-identified HIV activism in willingness to participate in HIV cure-related clinical trials? Results from the ANRS-APSEC study. J Virus Erad 2019;5(3):152–162.
  4. Protière C, Arnold MP, Fiorentino M, et al. Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS-APSEC study. A discrete choice experiment. Journal of the International AIDS Society 2020;23(2):e25443; doi: https://doi.org/10.1002/jia2.25443.
  5. Protière C, Fiorentino M, Sow A, et al. Who are the PLWH who might refuse to participate in HIV cure clinical trials with treatment interruption? Results from the ANRS-APSEC study. J Int AIDS Soc. 2020 Feb;23(2):e25443.; doi: 10.1097/QAD.0000000000002530.
  6. Protière C, Fressard L, Mora M, et al. Characterization of Physicians That Might Be Reluctant to Propose HIV Cure-Related Clinical Trials with Treatment Interruption to Their Patients? The ANRS-APSEC Study. Vaccines 2020;8(2); doi: 10.3390/vaccines8020334.
  7. Lefebvre S, Lelièvre J-D, Rieux V, et al. “They Have to Make an Effort Too”: What Decliners Can Teach Us About HIV Cure/Remission-Related Clinical Trials? Results from a French Qualitative Study. AIDS Research and Human Retroviruses 2025;41(1):20–29; doi: 10.1089/aid.2024.0064.
Chargement en cours...